Abivax
Abivax Logo
About Abivax
Abivax SA is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is an orally administered small molecule that enhances the expression of miR-124, a microRNA involved in immune regulation. Obefazimod is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. Abivax is also exploring additional indications for obefazimod and developing follow-on compounds from its proprietary chemical library. The company is headquartered in Paris, France.
Address
7-11 boulevard Haussmann,
Paris, 75009
France
Year founded
2013
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
